Health CarePharmaceuticals & Biotechnology
  • Price (JPY)7,155.00
  • Today's Change-39.00 / -0.54%
  • Shares traded947.80k
  • 1 Year change-8.49%
  • Beta1.0589
Data delayed at least 20 minutes, as of Nov 26 2021 06:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

  • Revenue in JPY (TTM)691.25bn
  • Net income in JPY62.51bn
  • Incorporated1941
  • Employees11.24k
  • Location
    Eisai Co LtdEisai Main Bldg., 4-6-10, KoishikawaBUNKYO-KU 112-8088JapanJPN
  • Phone+81 338173700
  • Fax+81 338113305
  • Websitehttps://www.eisai.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Medipal Holdings Corp3.27tn30.52bn485.14bn12.97k14.550.77498.840.1485136.35136.3514,639.422,560.321.9319.674.65251,788,700.002.402.636.517.426.627.131.241.331.06--0.04425.33-1.291.18-36.98-4.91-16.418.45
Sumitomo Dainippon Pharma Co Ltd548.18bn55.37bn570.99bn6.82k10.300.97918.431.04139.37139.371,379.801,465.690.43751.653.4880,355,320.002.914.404.246.4773.7474.836.658.841.37--0.294222.776.885.0537.9517.882.109.24
Nippon Shinyaku Co., Ltd.135.64bn29.19bn604.87bn2.06k19.873.3218.634.46433.39433.392,013.812,592.210.70551.423.5265,874,700.0015.199.6317.5211.4163.4755.5821.5314.214.25--0.0030.434.507.6822.7426.704.9328.73
Santen Pharmaceutical Co Ltd259.46bn7.32bn622.22bn4.23k85.281.9425.832.4018.2218.22648.27799.130.61742.523.1061,352,330.001.716.082.067.3160.9361.262.7810.212.2722.590.119444.963.335.03-71.10-33.7221.232.29
ONO PHARMACEUTICAL CO., LTD.332.89bn81.87bn1.32tn3.61k15.261.8513.403.97163.99163.99666.821,350.360.44992.363.9192,289,160.0011.089.1812.5510.5873.1572.8424.6221.012.92--0.01339.255.7714.0526.3324.737.586.79
Kyowa Kirin Co Ltd338.32bn42.45bn1.80tn5.42k42.292.5228.525.3378.9778.97629.421,327.480.41311.553.8562,385,580.005.185.635.756.3574.6168.9512.5512.984.96--0.025745.264.10-2.6624.839.5711.8811.97
Eisai Co., Ltd691.25bn62.51bn2.12tn11.24k32.822.8121.043.07218.03218.032,411.122,546.930.63221.963.8761,515,620.005.756.267.618.3676.6470.879.1010.501.71--0.106469.26-7.143.35-65.41-5.17-0.98131.30
Daiichi Sankyo Co Ltd1.01tn86.76bn5.73tn16.03k65.304.3039.615.6645.0545.05525.26684.620.48321.743.8363,139,
Data as of Nov 26 2021. Currency figures normalised to Eisai Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

33.66%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 30 Sep 202125.60m8.63%
Nomura Asset Management Co., Ltd.as of 15 Jul 202018.29m6.17%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 29 Oct 202110.00m3.37%
Asset Management One Co., Ltd.as of 15 Sep 20219.05m3.05%
Nikko Asset Management Co., Ltd.as of 29 Oct 20218.90m3.00%
Daiwa Asset Management Co. Ltd.as of 29 Oct 20218.85m2.99%
The Vanguard Group, Inc.as of 05 Nov 20216.56m2.21%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 04 Nov 20214.49m1.51%
BlackRock Fund Advisorsas of 04 Nov 20214.07m1.37%
Norges Bank Investment Managementas of 31 Dec 20204.01m1.35%
More ▼
Data from 31 Dec 2020 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.